Scaling drug purification from lab to factory
The Hidden Science of Scaling Up
A master chef who creates a perfect dish in a test kitchen may have no idea how to serve it to a million people without it spoiling, curdling, or losing its flavor That is the exact predicament facing modern drug development. Artificial intelligence and big data now flood the discovery pipeline with high-potential drug candidates. Yet the ability to mass-manufacture these miracle molecules safely for the global public has not kept pace. Moving drug making from the scale of a lab flask to a commercial bioreactor introduces non-linear biological and engineering shifts. These shifts can undermine even the most basic tasks, such as purification.
For decades, the pharmaceutical industry has known that what works in a petri dish often fails in a factory. The gap between designing a molecule and producing it at scale has been a quiet, persistent bottleneck. What has changed is the speed of discovery. AI now generates candidates far faster than the manufacturing infrastructure can handle. The pipeline is expanding — but the exit valve remains the same size.
A parallel exists in the semiconductor industry. For years, chip designers could create ever-more-complex circuits on paper, but the physical limits of etching those circuits onto silicon repeatedly held back progress. The solution came not from better design tools, but from breakthroughs in manufacturing precision. Drug purification faces a similar inflection point. The question is not whether we can imagine the next blockbuster drug, but whether we can build the factory that makes it real.
The Purification Process and Its Hidden Costs
Purification is the step that turns a promising chemical into a safe medicine. During this process, the desired drug molecule is separated from unwanted byproducts, contaminants, and biological debris. This is not a simple filtration. It requires precise chromatography, where the drug mixture passes through a column packed with a specialized resin. The resin binds the target molecule while letting impurities wash away. The resin itself is a critical component — a chromatography resin is a material designed to capture specific molecules based on their size, charge, or affinity.
The difficulty of purification increases as the process moves forward. Early steps are relatively forgiving. But as the drug becomes more concentrated and pure, the remaining impurities become harder to remove. The final polishing steps are the most demanding. A tiny error here can ruin an entire batch. When purification goes wrong, the human cost is not theoretical. Contaminated or impure drugs can cause severe side effects, allergic reactions, or even death. The stakes are high, and the margin for error is vanishingly small.
Henrik Ihre, a Distinguished Fellow at Cytiva, and Paul Belcher, a Business Leader at the same company, have observed this challenge firsthand. They note that small-scale success does not guarantee industrial-scale success. A process that works perfectly in a 10-liter flask may behave unpredictably when scaled to a 10,000-liter bioreactor. The non-linear shifts in biology and engineering mean that scientists cannot simply multiply the recipe. They must redesign the entire manufacturing approach.
The Expanding Drug
Pipeline and the Urgency of Innovation
The drug pipeline is growing faster than ever before. AI tools can now screen millions of compounds in silico, identifying candidates that would have taken years to find manually. This acceleration is a triumph of computational science. But it creates a new problem: the manufacturing capacity to produce these drugs safely is not expanding at the same rate. The bottleneck is not discovery — it is production. Every promising molecule that cannot be manufactured at scale is a potential cure that never reaches a patient.
When purification fails or is too slow, clinical trials are delayed. Patients wait longer for treatments. In some cases, entire drug programs are abandoned because the manufacturing cost is too high. The pharmaceutical industry is now searching for ways to close this gap. One approach is to design purification processes in parallel with drug discovery, rather than as an afterthought. Another is to develop more efficient chromatography resins that can handle higher volumes without losing selectivity.
In the early days of microchip manufacturing, the industry faced a similar scaling crisis. The solution came from a combination of process innovation and materials science. Companies invested heavily in automated fabrication lines and new materials that could withstand the demands of mass production. Drug purification is at a similar crossroads. The next breakthrough will likely come not from a single new drug, but from a new way to make many drugs at once.
Sources
1. Cytiva